Juliane Proft is Project Manager in Oncology at IOCB (Institute of Organic Chemistry and Biochemistry), located in Prague, Czech Republic. IOCB is joining us to the 6th BioFit edition in order to present its technology, open for co-development and out licensing contact. She accepted to share with us the reasons why IOCB comes to BioFIT.

BioFIT : What is IOCB ? 

Juliane Proft : IOCB is a public research institution located in Prague, Czech Republic, part of the Academy of Sciences. In more than 60 years of its history it has been focused on fundamental research in Organic Chemistry, Biochemistry, Theoretical Chemistry and Chemistry of Natural compounds. The institute has also a tradition in the translation of results from basic research into practical applications, mainly in the field of human and veterinary medicine. A prominent example is Tenoforvir, an HIV drug developed in collaboration with the KU Leuven and Gilead Scientific. This translational effort continues, in 2017 we have signed license agreements with two major partners.

IOCB TTO Group © – Juliane (on the front) and the rest of the group of IOCB

What are IOCB’s projects about ?

Most of our projects are developed around small molecules aiming at unmet medical needs like cancer, CNS diseases, viral and bacterial infections, metabolic syndrome and others. With around 40 research groups in various disciplines of chemistry, new projects are constantly evolving at the IOCB.

Why do you come to BioFIT ?

BioFIT is for us a good platform to meet with potential partners and we have made some fruitful connections in the past years. We are seeking for commercial partners to out-license and/or co-develop our technologies.

Many thanks to Juliane Proft for these comments.

BioFIT’s prestigious Steering Committee have defined the content of the BioFIT 2014 Conference Program during their last meeting on November 25th, 2013.

BioFIT 2014 presents for this edition a dense and rich program organized around 3 main tracks and 12 sessions covering the future of public/private collaborations, dealmaking, financing and technology transfer issues and operating as a tool-box program for the various actors of this sector.

Plenary Session:

Accessing innovation: how to build long term partnerships?

Track 1:

Emerge, last and deliver: best practices in collaborative research

New models for bridging the gap from research to market
Big consortia: how do they work and what are their outcomes?
Emerge & happen: creative solutions to difficult problems in dealmaking
Make it work and last: how to best apply strategic alliance management
Looking ahead: how can big data be transformed into knowledge?
Biotech meets Medtech: towards an intensified collaboration

Track 2:

Early stage innovation: new routes to funding sources

Who will be funding the maturation phase in the future?
New practices from the VC industry in sourcing innovation
The road less traveled: new approaches to finance early stage innovation

Track 3:

Creative solutions for transferring innovation to market : TTO’s and industry’s new approaches

Driving innovation in Europe: using Horizon 2020 program
Scouting innovation: academia push and industry pull
The valuation process: do all stakeholders use the same criteria?

Full Program